Hypothesis

Intermittent, low‑dose GH pulses paired with liver‑specific knockdown of IGF‑1 production will preserve muscle and bone anabolism while maintaining circulating IGF‑1 in the range associated with improved insulin sensitivity and longevity.

Rationale

• Somatopause drives sarcopenia and metabolic dysfunction, yet centenarians exhibit low IGF‑1 bioactivity alongside preserved insulin sensitivity (2).
• GH replacement improves lean mass and bone density but provokes insulin resistance, hyperglycemia, and oncogenic risk (3).
• Hepatic IGF‑1 accounts for ~75 % of circulating IGF‑1; muscle‑derived IGF‑1 acts locally and is less tied to systemic metabolic effects (1).
• An inverse U‑shaped relationship links IGF‑1 levels to metabolic syndrome, with both excess and deficiency worsening risk (5).
• Sex‑specific signaling shows IGF‑1 dominates female aging while insulin signaling is more influential in males (6).

By suppressing hepatic IGF‑1 we aim to shift the systemic IGF‑1 curve leftward into the favorable low‑normal zone, while pulsatile GH spikes provide transient activation of muscle and bone IGF‑1 receptors, delivering anabolic signals without sustaining high systemic IGF‑1 that drives insulin resistance and tumorigenesis.

Predictions

1. Circulating IGF‑1 will remain 20‑30 % below youthful levels but above the severe deficiency seen in Global GH‑KO mice.
2. Muscle mass and bone density will increase comparably to continuous GH therapy (3).
3. Insulin tolerance and fasting glucose will improve relative to continuous GH treatment, resembling the phenotype of IGF‑1‑low centenarians (2).
4. Visceral adipose inflammation (γδ T‑cell infiltration) will not exacerbate, as low systemic IGF‑1 reduces inflammasome priming (4).
5. Tumor incidence in aged rodents will not rise above baseline, contrasting with the elevated cancer risk observed with chronic GH replacement.

Experimental Design

Model: 20‑month‑old C57BL/6J mice (both sexes). Groups (n=15 per sex):

• Vehicle control
• Continuous GH (0.1 mg/kg/day, subcutaneous)
• Pulsatile GH (0.1 mg/kg every 48 h, mimicking secretory bursts)
• Liver‑specific IGF‑1 siRNA (AAV8‑TF‑siIGF1, single dose)
• Combined pulsatile GH + liver IGF‑1 siRNA

Intervention duration: 16 weeks. Outcomes:

• Serum IGF‑1, GH, insulin, glucose (ELISA, fasting)
• Dual‑energy X‑ray absorptiometry for lean/fat mass and bone mineral density
• Hyperinsulinemic‑euglycemic clamp for insulin sensitivity
• Flow cytometry of visceral adipose γδ T cells (4)
• Histopathology of liver, lung, and mammary glands for neoplasia
• RNA‑seq of gastrocnemius to verify IGF‑1 receptor pathway activation

Statistical analysis: Two‑way ANOVA (treatment × sex) with post‑hoc Tukey; significance set at p<0.05.

Potential Implications

If validated, this strategy would provide a mechanistic bridge between the longevity benefits of reduced IGF‑1 signaling and the clinical need to counteract age‑related musculoskeletal decline. It suggests that spatially and temporally restricted IGF‑1 modulation—rather than global GH blockade or replacement—can optimize the trade‑off between anabolism and metabolic health. Success would prompt translation to larger mammals and early‑phase human trials using liver‑targeted antisense oligonucleotides or CRISPR‑based epigenetic editors alongside FDA‑approved GH secretagogues administered in a pulsatile regimen.